Nrti published presentations and documents on DocSlides.
Jim Demarest. ,. 1. Mark Underwood,. 2. Marty S...
r. + 3TC. OLE . Study. LPV/. r. bid + 3TC or FT...
SPARTAN. PROGRESS. NEAT001/ANRS 14. 3 . MODERN. R...
Are NRTI’s Necessary?. Brian R. Wood, MD. Assis...
Vincent Marconi, . MD. Outline. Transmitted Drug ...
FLAMINGO. GS-236-0103. ACTG . A5257. WAVES. . De...
ZDV/3TC . vs. TDF + FTC. Study 934. ABC/3TC . vs...
EFV vs LPV/r vs EFV + LPV/r . A5142. Mexican. . ...
David Spach, MD. Principal . Investigator, NW AET...
SPARTAN. PROGRESS. RADAR. NEAT001/ANRS 14. 3. A40...
Chief, Division of Infectious Diseases. Weill Med...
New Treatments for HIV. C. Ryan Tomlin, . Pharm.D...
Camille Angle, Meagan Bardan, Hanna Schimjawicz a...
Drew Lambert, . PharmD. lambertd@husson.edu. Huss...
ATV/r 300/100 mg QD 3TC 300 mg QD. N = 133. N =...
, . prodrug. of . temsavir. . (attachment inhib...
Medical Director, Specialty . Services. Southwest ...
Study. LPV/. r. bid + 3TC or FTC . qd. + NRTI. N ...
WHO HQ. The role of DTG based regimens in first- a...
Clinical Pharmacist – HIV Medicine. Outline. Wha...
Dolutegravir based regimens in first- ad second-li...
TOTEM. Switching the NRTI Backbone to Tenofovir DF...
Supported by an educational grant from Gilead Scie...
by Baseline NRTI Resistance . and Second-Line NRTI...
SPRING-2 Study. Dolutegravir. versus Raltegravir....
RADAR. NEAT001/ANRS 14. 3 . A4001078. VEMAN. MODER...
Etraswitch. . Study. : Switch PI/r to ETR. Contin...
Copyright © 2024 DocSlides. All Rights Reserved